Scholarlink

<p>The trimethylamine (TMA)-trimethylamine-N-oxide (TMAO) pathway, involving gut microbiota-derived metabolites, may play a role in advanced chronic liver disease (ACLD). This study assessed TMA and TMAO levels in ACLD patients and their associations with liver-related outcomes. Plasma samples from 66 ACLD patients (30 compensated, 36 decompensated) and 11 healthy controls were analyzed using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry LC-MS/MS. Associations with clinical outcomes: hepatic decompensation, hepatocellular carcinoma, acute kidney injury, liver transplantation or death, and major cardiovascular events, were assessed using statistical models.TMAO levels were slightly elevated in ACLD patients, but not significantly different from controls (<i>p</i> = 0.649). The TMAO/TMA ratio negatively correlated with Child-Pugh score (<i>r</i> = −0.31, <i>p</i> = 0.02). Higher TMA levels were associated with increased risk of liver-related events (HR: 1.36; <i>p</i> = 0.003).TMA, rather than TMAO, may serve as a prognostic marker in ACLD. Further research is needed to elucidate its role in disease progression and therapeutic potential.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the trimethylamine pathway in advanced chronic liver disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月15日

查看全文
  • Jil T. Bürki,
  • Jonas Schropp,
  • Peter Neyer,
  • Christian Steuer,
  • Jaume Bosch,
  • Annalisa Berzigotti,
  • Susana G. Rodrigues

摘要

The trimethylamine (TMA)-trimethylamine-N-oxide (TMAO) pathway, involving gut microbiota-derived metabolites, may play a role in advanced chronic liver disease (ACLD). This study assessed TMA and TMAO levels in ACLD patients and their associations with liver-related outcomes. Plasma samples from 66 ACLD patients (30 compensated, 36 decompensated) and 11 healthy controls were analyzed using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry LC-MS/MS. Associations with clinical outcomes: hepatic decompensation, hepatocellular carcinoma, acute kidney injury, liver transplantation or death, and major cardiovascular events, were assessed using statistical models.TMAO levels were slightly elevated in ACLD patients, but not significantly different from controls (p = 0.649). The TMAO/TMA ratio negatively correlated with Child-Pugh score (r = −0.31, p = 0.02). Higher TMA levels were associated with increased risk of liver-related events (HR: 1.36; p = 0.003).TMA, rather than TMAO, may serve as a prognostic marker in ACLD. Further research is needed to elucidate its role in disease progression and therapeutic potential.